Matthew J Hatter, Zach Pennington, Timothy I Hsu, Tara Shooshani, Olivia Yale, Omead Pooladzandi, Sean S Solomon, Bryce Picton, Marlena Ramanis, Nolan J Brown, Sohaib Hashmi, Yu-Po Lee, Nitin Bhatia, Martin H Pham
OBJECTIVE: Tranexamic acid (TXA) is an FDA-approved antifibrinolytic that is seeing increased popularity in spine surgery owing to its ability to reduce intraoperative blood loss (IOBL) and allogeneic transfusion requirements. The present study aimed to summarize the current literature on these formulations in the context of short-segment instrumented lumbar fusion including ≥ 1-level posterior lumbar interbody fusion (PLIF). METHODS: The PubMed, Cochrane, and Web of Science databases were queried for all full-text English studies evaluating the use of topical TXA (tTXA), systemic TXA (sTXA), or combined tTXA+sTXA in patients undergoing PLIF...
May 17, 2024: Journal of Neurosurgery. Spine